studies suggested optimal diagnostic cutoffs of 450, 900, and 1,800 pg/ml for age categories of <50, 50 to 75, and >75 years, respectively, for the identification of acute HF (9) , along with an age-independent cutoff of 300 pg/ml to exclude acute HF. These cutoffs have been widely endorsed (1, 5, 10) ; however, they differ substantially from the Food and Drug Administration (FDA)-approved cutoffs for NT-proBNP (125 and 450 pg/ml for <75 and $75 years of age) (11), which are optimized for outpatient exclusion of ambulatory HF.
Thus, there is a need to reconsider which cutoffs should be used, as continued reliance on current, approved cutoffs has the potential for diagnostic inaccuracy, particularly for test specificity.
In light of these current gaps, the aim of the ICON-
RELOADED (ICON: Re-evaluation of Acute Diagnostic
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A blood sample was taken at enrollment. STATISTICAL ANALYSES. The study was designed to include 1,765 patients to ensure a sample size of at least 1,500 analyzable patients, assuming 15% attrition.
Receiver-operating characteristic (ROC) curves for performance of NT-proBNP for diagnosis of acute HF were constructed. Operating characteristics for each cutoff for rule-in and the proposed cutoff for rule-out relative to the gold-standard diagnosis were evaluated, including sensitivity, specificity, PPV, NPV, LRþ, and LRÀ. Estimates and 95% confidence intervals (CIs) were determined for the NPV and PPV parameters (13) , and separately for LRþ and LRÀ using a nonlinear mixed-effects model. The significance of an elevated age-adjusted NT-proBNP value was further assessed by multivariable logistic regression analyses using backward elimination.
Variables entered into the model were pre-specified as: history of diabetes mellitus, hypertension, or prior HF; history including a chief complaint of orthopnea; physical examination findings of pulmonary rales or peripheral edema; and testing results including estimated glomerular filtration rate, chest radiography revealing interstitial edema, as well as an elevated age-adjusted NT-proBNP. Variables were retained in the final model with an alpha level of 0.2; odds ratios (ORs) with 95% CIs were generated along with estimation of an overall C-statistic for the model.
Based on data generated in the ICON study (9) , overall sensitivity and specificity of the proposed age-dependent cutoffs were expected to be 90.0% and 84.0%, respectively. The expected prevalence of acute HF was 50% with a PPV of 85.0%, and the LRþ was expected to be 5.62. This expectation was based on the prevalence observed in the original ICON study (9) . With 1,500 analyzable patients and an assumed HF prevalence of 50% (9), the anticipated lower bounds of a 95% 2-sided CI for the hypothesized PPV and LRþ were 86.2% and 4.77, respectively (14) . With 1,275 analyzable patients from the United States, the lower bounds were anticipated to be 82.5% and 4.6 for PPV and LRþ, respectively.
The expected sensitivity and specificity values of the rule-out cutoff of 300 pg/ml were 99.0% and 60.0%, respectively (9) . Thus, the expected NPV was 98.5% (96.7% lower bound of the 95% CI) and the expected LRÀ was 0.017 (0.034 upper bound of the 
NT-proBNP in the Emergency Department with acute HF had LVEF <50%.
Baseline characteristics of the subgroup of patients with acute HF, comparing those with reduced versus preserved ejection fraction, are presented in Online Table 2 . CUTPOINT ANALYSIS: IDENTIFICATION OF ACUTE HF. The diagnostic sensitivities, specificities, PPV and NPV, and likelihood ratios for age-stratified diagnostic cutpoints in the study population are depicted in The age-independent approach for ruling out acute HF using the single cutpoint of 300 pg/ml exhibited an NPV (primary endpoint) of 98.0% (95% CI: 96.9% to 98.8%), and a specificity of 71.7% (95% CI: 69.1% to 74.3%). The LRÀ was 0.09 (95% CI: 0.05 to 0.13) in our patient population ( Table 2) .
SUBGROUP FINDING. Subgroup analyses assessing the AUC of the optimal NT-proBNP cutpoints for the diagnosis or exclusion of acute HF are presented in The receiver-operating characteristic curves for the NT-proBNP-based diagnosis of acute heart failure are presented for (A) all patients (n ¼ 1,461), and (B) across the 3 age groups: <50 years of age (n ¼ 462); 50 to 75 years of age (n ¼ 833); and >75 years of age (n ¼ 166). The sensitivity, specificity, PPV, NPV, and accuracy are presented for the Youden index (A) for all patients, and (B) for each age group. AUC ¼ area under the curve; HF ¼ heart failure; NPV ¼ negative predictive value;
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; PPV ¼ positive predictive value; ROC ¼ receiver-operating characteristic.
Januzzi, Jr. et al. The sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios are presented as % (95% confidence interval) for the age-dependent rule-in cutoffs of 450, 900, and 1,800 pg/ml for ages <50, 50-75, >75 years, and for the rule-out cutoff of 300 pg/ml, in all enrolled subjects.
HF ¼ heart failure; LRþ ¼ positive likelihood ratio; LRÀ ¼ negative likelihood ratio; NPV ¼ negative predictive value; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; PPV ¼ positive predictive value.
lower than projected (vs. 50%); in comparison, a recent report from Singapore and New Zealand confirms reduced prevalence of HF in dyspneic patients (36% and 24%, respectively) (19) . This may suggest Tables 2 and 3 . STUDY LIMITATIONS. The clearest limitation of the study is that fewer than expected patients with acute HF were enrolled, which is reflected in the lower PPV result, as PPV is largely dependent on the prevalence of the disease. For example, the same assay tested here would have a PPV of 80% to 90% if the prevalence of acute HF was 50%. As a matter of fact, the PPV noted in this study was exactly as projected based on the lower prevalence of acute HF (Online Figure 1) . In this regard, the use of LRþ to express the performance of a test is arguably a more reliable approach when comparing tests from 2 different studies with different disease prevalence, and the results confirm the expected performance of the ageadjusted cutoff approach studied in this analysis.
Similarly, in the BNP (Breathing Not Properly) multinational study (4), which had a higher prevalence of patients with HF (47%), the PPV was indeed higher (71% to 83%, depending upon the BNP level), but the LRþ was lower (3.4) when evaluating BNP $100 pg/ml (26) . As with BNP, certain clinical factors, such as impaired renal function, can increase NT-proBNP levels in the absence of HF and deliver a lower specificity as well as PPV. However, age stratification largely addresses the effects of renal function (16) . As seen in the AUC curve, using a higher NT-proBNP cutpoint would result in better specificity and better PPV, as was the case of BNP in the Breathing Not Properly Study (4) . Lower prevalence of acute HF in this study likely reflects the evolution in practices surrounding ED use for HF over the last decade, in favor of urgent care and office-based practice. It is important to note that despite the lower prevalence of acute HF in the study cohort, the performance of the cutoffs for exclusion of acute HF was great.
Lastly, because this study was conducted in the United States and Canada, the generalizability of the findings outside of this geographic region may be limited.
CONCLUSIONS
The ICON-RELOADED study demonstrates that the NT-proBNP cutoffs proposed in the first ICON study perform consistently in a current, multicenter cohort of all-comer patients. As in all prior studies of BNP or NT-proBNP, our results confirm that elevated NTproBNP may aid in identification of acute HF, whereas an NT-proBNP <300 pg/ml provides a strong ability to exclude acute HF. Despite changes in prevalence, demographics, comorbidities, and management of patients with HF nearly 15 years after NTproBNP was first developed as a biomarker test, the utility of the assay for both the diagnosis and exclusion of acute HF in the ED setting endures.
